{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:18:09Z","timestamp":1790835489330,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Alpha-synucleinopathies, such as Parkinson\u2019s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases. A diagnosis may be challenging because clinical symptoms partially overlap, and there is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study, the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-NfL was significantly elevated in patients with DLB and MSA compared to patients with PD or control donors. To differentiate between groups, receiver operating characteristic (ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the area under the curve (AUC) values of 0.87\u20130.92 for CSF-NfL. Furthermore, we observed that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels remained unregulated. Our study suggests NfL as a promising marker to discriminate between different types of alpha-synucleinopathies or between DLB\/MSA and controls.<\/jats:p>","DOI":"10.3389\/fnagi.2021.717930","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T06:41:04Z","timestamp":1632292864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies"],"prefix":"10.3389","volume":"13","author":[{"given":"Sezgi","family":"Canaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villar-Piqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Gmitterov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Varges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","article-title":"CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson\u2019s disease.","volume":"28","author":"Abdo","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1007\/s12035-015-9133-2","article-title":"Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease.","volume":"53","author":"Cramm","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12035-014-8709-6","article-title":"Characteristic CSF prion seeding efficiency in humans with prion diseases.","volume":"51","author":"Cramm","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","article-title":"Prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the EUROPARKINSON collaborative study.","volume":"62","author":"De Rijk","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1515\/CCLM.2011.077","article-title":"\u03b1-Synuclein in Parkinson disease and other neurodegenerative disorders.","volume":"49","author":"Eller","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/a:1007677003387","article-title":"Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000).","volume":"25","author":"Eng","year":"2000","journal-title":"Neurochem. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","article-title":"Consensus statement on the diagnosis of multiple system atrophy.","volume":"163","author":"Gilman","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy.","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or Parkinsonian disorders.","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/mds.870130116","article-title":"Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson\u2019s disease.","volume":"13","author":"Holmberg","year":"1998","journal-title":"Mov. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.","volume":"136","author":"Ishiki","year":"2016","journal-title":"J. Neurochem."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/c2009-1-03732-0","author":"Kompoliti","year":"2010","journal-title":"Encyclopedia of Movement Disorders."},{"key":"B13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41467-020-14373-2","article-title":"Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia.","volume":"11","author":"Llorens","year":"2020","journal-title":"Nat. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jalz.2016.09.013","article-title":"Evaluation of \u03b1-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.","volume":"13","author":"Llorens","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00415-016-8259-0","article-title":"Cerebrospinal \u03b1-synuclein in \u03b1-synuclein aggregation disorders: tau\/\u03b1-synuclein ratio as potential biomarker for dementia with Lewy bodies.","volume":"263","author":"Llorens","year":"2016","journal-title":"J. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies.","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","article-title":"CSF \u03b1-synuclein and UCH-L1 levels in Parkinson\u2019s disease and atypical parkinsonian disorders.","volume":"20","author":"Mondello","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations.","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","article-title":"Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.","volume":"70","author":"Savica","year":"2013","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13195-014-0072-3","article-title":"Biomarkers in biological fluids for dementia with Lewy bodies.","volume":"6","author":"Schade","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/nprot.2016.120","article-title":"The real-Time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases.","volume":"11","author":"Schmitz","year":"","journal-title":"Nat. Protoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s12035-015-9167-5","article-title":"Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic.","volume":"53","author":"Schmitz","year":"","journal-title":"Mol. Neurobiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1007\/s12035-018-1313-4","article-title":"Cerebrospinal fluid total and phosphorylated \u03b1-synuclein in patients with Creutzfeldt\u2013Jakob disease and synucleinopathy.","volume":"56","author":"Schmitz","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-synuclein in Lewy bodies [8].","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"\u03b1-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy.","volume":"249","author":"Wakabayashi","year":"1998","journal-title":"Neurosci. Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/biom9120800","article-title":"Evaluation of human cerebrospinal fluid malate dehydrogenase 1 as a marker in genetic prion disease patients.","volume":"9","author":"Zerr","year":"2019","journal-title":"Biomolecules"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.717930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T06:41:07Z","timestamp":1632292867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.717930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":31,"alternative-id":["10.3389\/fnagi.2021.717930"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.717930","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"717930"}}